investors & media

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

9/21/2021

BLA submission based on data from Phase 1/2 and Phase 3 Northstar studies, which represent more than 220 patient-years of experience with beti-cel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- bluebird bio, Inc . (Nasdaq: BLUE) today announced it has completed the rolling submission of its

Read more
9/13/2021

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2021-- 2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy. Session One: An Introduction to 2seventy’s

Read more
9/8/2021

Proceeds to support both bluebird bio and 2seventy bio’s pipeline of novel cell therapy programs Business separation of bluebird and 2seventy expected to be completed in October 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 8, 2021-- bluebird bio, Inc.

Read more